Prenetix Non-Invasive Prenatal Test

To detect the most frequent chromosomal abnormalities at the early stages of pregnancy, screening approaches based on the analysis of fetal genetic material present in the maternal blood have been developed. The Non-Invasive Prenatal Testing (NIPT) is currently considered to be the expert screening that complements the conventional screening of the 1st trimester of pregnancy by making it more accurate due to the reduced number of false positive results.

The testing is performed beginning from the 10th week of pregnancy using the maternal venous blood as a test material.

The main advantages of Prenetix Non-Invasive Prenatal Testing are as follows:

  1. High reliability /accuracy/ (over 99% in case of trisomy 21 (Down syndrome)).
  2. Extremely low probability of false positive results (less than 0.1%). The use of Prenetix NIPT reduces the number of invasive studies by 88%, and decreases the number of cases of pregnancy terminated as a result of invasive diagnostic procedures by 94%.
  3. Low frequency of repeated sampling.
  4. The most clinically validated technology (the results of blind clinical studies in more than 23,000 women of different ages and risk categories have been published).



Contact us
(english speaking call center):
8 (800) 250-90-75